

## Product Analysis Certificate

Ready-to-Use Lentiviral Packaging Plasmid Mix  
Cat.# CPCP-K2A



### Ready-to-Use Lentiviral Packaging Plasmid Mix

**Product:** Ready-to-Use Lentiviral Packaging Plasmid Mix

**Catalog #:** CPCP-K2A

**Lot #:** 17051710

#### Description:

The Ready-to-Use Lentiviral Packaging Plasmid Mix is a mixture of the human immunodeficiency virus (HIV) lentiviral packaging plasmid psPAX2 (Addgene, Cat.# 12260) and the pMD2.G plasmid (Addgene, Cat.# 12259) containing VSV-G. These plasmids provide all the necessary structural, regulatory, and replication proteins required to produce pseudotyped packaged lentiviral expression constructs when co-transfected with an HIV-based lentiviral expression construct (e.g. Collecta pRSI shRNA expression construct) into a producer 293T cell line (e.g. ATCC, Cat.# CRL-11268™). Pseudotyped lentiviral particles with VSV-G envelope protein can infect a variety of mammalian or non-mammalian, dividing or non-dividing cells. The kit contains 250 µg of lentiviral packaging plasmid mix that will be sufficient for 25 transfections in 10-cm culture plates.

The Ready-to-Use Packaging Plasmid Mix is compatible with most commercially-available second- and third-generation lentiviral vectors.

**Biosafety Level:** BSL-2

**Storage:** -20°C

**Shelf Life:** 2 years from date of receipt with proper storage

**Shipping Conditions:** Blue Ice or Dry Ice

#### Contents:

| # | Catalog # | Description   |
|---|-----------|---|
| 1 | CPCP-K2A  | <b>Ready-to-Use Lentiviral Packaging Plasmid Mix</b><br>250 µg, 0.5 µg/µl (500 µl × 1 vial) |

#### Quality Control:

10 µg of Ready-to-Use Lentiviral Packaging Plasmid mix and 2 µg of pRSI16-U6-(sh)-UbiC-TagRFP-2A-Puro were co-transfected into ATCC 293T/17 (ATCC Cat.# CRL-11268™) producer cells with Lipofectamine® Reagent and PLUS™ Reagent (Thermo Fisher) in a 10-cm culture plate as described in the **Packaging, Titering, and Transduction of Lentiviral Constructs** User Manual. After transformation, the pRSI16 viral titer was  $>1 \times 10^6$  TU/ml as determined by FACS analysis of 293T/17 cells infected by the pseudoviral supernatant.

## Product Analysis Certificate

Ready-to-Use Lentiviral Packaging Plasmid Mix  
Cat.# CPCP-K2A



---

## PROTOCOLS

Please visit Collecta's website for the latest protocols:  
<https://www.cellecta.com/resources/product-manuals-and-certificates/>

---

## Technical Support

Phone: +1 (650) 938-3910  
Toll-Free: +1 (877) 938-3910  
Fax: +1 (650) 938-3911

E-mail:  
Technical Support: [tech@cellecta.com](mailto:tech@cellecta.com)  
General Information: [info@cellecta.com](mailto:info@cellecta.com)  
Sales: [sales@cellecta.com](mailto:sales@cellecta.com)  
Orders: [orders@cellecta.com](mailto:orders@cellecta.com)

Blog: <https://www.cellecta.com/company/blog-news/>

---

## Safety Guidelines

The HIV-based lentivector system is designed to maximize its biosafety features, which include:

- A deletion in the enhancer of the U3 region of 3'ΔLTR ensures self-inactivation of the lentiviral construct after transduction and integration into genomic DNA of the target cells.
- The RSV promoter upstream of 5'LTR in the lentivector allows efficient Tat-independent production of viral RNA, reducing the number of genes from HIV-1 that are used in this system.
- Number of lentiviral genes necessary for packaging, replication and transduction is reduced to three (gag, pol, rev). The corresponding proteins are expressed from different plasmids lacking packaging signals and share no significant homology to any of the expression lentivectors, pVSV-G expression vector, or any other vector to prevent generation of recombinant replication-competent virus.
- None of the HIV-1 genes (gag, pol, rev) will be present in the packaged pseudoviral genome, as they are expressed from packaging plasmids lacking packaging signal—therefore, the lentiviral particles generated are replication-incompetent.
- Pseudoviral particles will carry only a copy of your expression construct.

Despite the above safety features, use of HIV-based vectors falls within NIH Biosafety Level 2 criteria due to the potential biohazard risk of possible recombination with endogenous viral sequences to form self-replicating virus or the possibility of insertional mutagenesis. For a description of laboratory biosafety level criteria, consult the Centers for Disease Control Office of Health and Safety Web site at:

[https://www.cdc.gov/biosafety/publications/bmb15/bmb15\\_sect\\_iv.pdf](https://www.cdc.gov/biosafety/publications/bmb15/bmb15_sect_iv.pdf)

It is also important to check with the health and safety guidelines at your institution regarding the use of lentiviruses and follow standard microbiological practices, which include:

- Wear gloves and lab coat at all times when conducting the procedure.
- Always work with pseudoviral particles in a Class II laminar flow hood.
- All procedures are performed carefully to minimize the creation of splashes or aerosols.
- Work surfaces are decontaminated at least once a day and after any spill of viable material.
- All cultures, stocks, and other regulated wastes are decontaminated before disposal by an approved decontamination method such as autoclaving. Materials to be decontaminated outside of the immediate laboratory area are to be placed in a durable, leakproof, properly marked (biohazard, infectious waste) container and sealed for transportation from the laboratory.


## Product Analysis Certificate

Ready-to-Use Lentiviral Packaging Plasmid Mix  
Cat.# CPCP-K2A



## Appendix

### 1. Packaging Plasmid Maps



For detailed maps, sequences, feature maps, and restriction maps for psPAX2 and pMD2.G, please see the Addgene website:

**psPAX2:** <http://www.addgene.org/12260/>

**pMD2.G:** <http://www.addgene.org/12259/>

For maps, sequences, and cassette designs for standard lentiviral expression vectors, please visit <https://www.cellecta.com/resources/vector-information/>

For all other vectors, please contact Cellecta at [tech@cellecta.com](mailto:tech@cellecta.com).

## Product Analysis Certificate

Ready-to-Use Lentiviral Packaging Plasmid Mix  
Cat.# CPCP-K2A



---

### Terms and Conditions

#### Cellecta, Inc. Limited License

Cellecta grants the end user (the "Recipient") of the Ready-to-Use Lentiviral Packaging Plasmid Mix (the "Product") a non-transferable, non-exclusive license to use the reagents for internal research use only as described in the enclosed protocols; in particular, research use only excludes and without limitation, resale, repackaging, or use for the making or selling of any commercial product or service without the written approval of Cellecta, Inc. -- separate licenses are available for non-research use or applications. The Product is not to be used for human diagnostics or included/used in any drug intended for human use. Care and attention should be exercised in handling the Product by following appropriate research laboratory practices.

Cellecta's liability is expressly limited to replacement of Product or a refund limited to the actual purchase price. Cellecta's liability does not extend to any damages arising from use or improper use of the Product, or losses associated with the use of additional materials or reagents. This limited warranty is the sole and exclusive warranty. Cellecta does not provide any other warranties of any kind, expressed or implied, including the merchantability or fitness of the Product for a particular purpose. Use of the Product for any use other than described expressly herein may be covered by patents or subject to rights other than those mentioned. Cellecta disclaims any and all responsibility for injury or damage that may be caused by the failure of the Recipient or any other person to use the Product in accordance with the terms and conditions outlined herein.

The Recipient may refuse these licenses by returning the enclosed Product unused. By keeping or using the enclosed Product, you agree to be bound by the terms of these licenses. The laws of the State of California shall govern the interpretation and enforcement of the terms of these Licenses.

#### Limited Use Licenses

The Recipient acknowledges that Product has been developed by Cellecta based on licenses from Third Parties and agrees with the Terms of Limited Use for the Recipient provided by the Third Parties:

#### Life Technologies Corporation End-User Label License for the use of Lentiviral Expression System:

"This product or service (based upon the Lentiviral Expression System) is sublicensed from Life Technologies Corporation under U.S. Patent Nos. 5,686,279; 5,834,256; 5,858,740; 5,994,136; 6,013,516; 6,051,427; 6,165,782; 6,218,187; 6,428,953; 6,924,144; 7,083,981 and 7,250,299 and corresponding patents and applications in other countries for internal research purposes only. Use of this technology for gene therapy applications or bioprocessing other than for nonhuman research use requires a license from GBP IP, LLC. Please contact GBP IP, LLC 537 Steamboat Road, Suite 200, Greenwich, CT 06830. Use of this technology to make or sell products or offer services for consideration in the research market requires a license from Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008."

Terms and Conditions are also available online at <https://www.cellecta.com/company/legal-information/terms-and-conditions/>.

© 2017 Cellecta, Inc. All Rights Reserved.

#### Trademarks

CELLECTA is a registered trademark of Cellecta, Inc. CRL-11268 is a trademark of ATCC. Invitrogen, Lipofectamine, and PLUS Reagent are trademarks of Thermo Fisher Scientific.